These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 38791907)

  • 1. Abemaciclib for the Treatment of HR+HER2- Metastatic Breast Cancer: An Institutional Experience.
    Matos E; Cankar K; Režun N; Dejanović K; Ovčariček T
    Cancers (Basel); 2024 May; 16(10):. PubMed ID: 38791907
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world treatment patterns and outcomes of abemaciclib for the treatment of HR+, HER2- metastatic breast cancer.
    Cuyun Carter G; Sheffield KM; Gossai A; Huang YJ; Zhu YE; Bowman L; Nash Smyth E; Mathur R; Cohen AB; Rasmussen E; Balakrishna S; Morato Guimaraes C; Rybowski S; Seidman AD
    Curr Med Res Opin; 2021 Jul; 37(7):1179-1187. PubMed ID: 33970738
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-World Effectiveness of Palbociclib Plus Letrozole vs Letrozole Alone for Metastatic Breast Cancer With Lung or Liver Metastases: Flatiron Database Analysis.
    Brufsky A; Liu X; Li B; McRoy L; Layman RM
    Front Oncol; 2022; 12():865292. PubMed ID: 35860587
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real world incidence and management of adverse events in patients with HR+, HER2- metastatic breast cancer receiving CDK4 and 6 inhibitors in a United States community setting.
    Price GL; Sudharshan L; Ryan P; Rajkumar J; Sheffield KM; Nash Smyth E; Morato Guimaraes C; Rybowski S; Cuyun Carter G; Gathirua-Mwangi WG; Huang YJ
    Curr Med Res Opin; 2022 Aug; 38(8):1319-1331. PubMed ID: 35535675
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Abemaciclib for treating patients with HR+/HER2- metastatic breast cancer: a real-world study in France, Italy and Spain.
    Blancas I; Grosjean J; Pedersini R; Buzzoni C; Sleilaty G; Molero A; Tamma A; Chouaki N; Atienza M; Emde A; Siddi S; Bayona RS; Mastro LD; Fakhouri W
    Future Oncol; 2024 Aug; ():1-14. PubMed ID: 39115881
    [No Abstract]   [Full Text] [Related]  

  • 6. Real-world treatment patterns and effectiveness of palbociclib plus an aromatase inhibitor in patients with metastatic breast cancer aged 75 years or older.
    Brufsky A; Liu X; Li B; McRoy L; Chen C; Layman RM; Rugo HS
    Front Oncol; 2023; 13():1237751. PubMed ID: 37841423
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-World Analysis of Clinical and Demographic Characteristics, Treatment Patterns, and Outcomes in Predominantly Older Patients with HR+/HER2- Metastatic Breast Cancer Receiving Abemaciclib in Routine Clinical Practice.
    Ring A; Karuturi M; Smyth EN; Lokhandwala T; Sheffield KM; Willey J; Lunacsek O; Sapunar F; Cui ZL; Coutinho AD; Rybowski S
    Drugs Real World Outcomes; 2023 Dec; 10(4):589-603. PubMed ID: 37775689
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of abemaciclib-based therapy versus tucidinostat-based therapy after progression on palbociclib in patients with HR
    Yuan Y; Zhang S; Wang T; Wang B; Wang S; Shi J; Sun T; Yin Y; Ouyang Q; Li J; Wen Y; Zhang L; Jiang Z
    Transl Breast Cancer Res; 2023; 4():10. PubMed ID: 38751483
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First-line real-world treatment patterns and survival outcomes in women younger or older than 40 years with metastatic breast cancer in the real-life multicenter French ESME cohort.
    Galvin A; Courtinard C; Bouteiller F; Gourgou S; Dalenc F; Jacot W; Arnedos M; Bailleux C; Dieras V; Petit T; Emile G; Dubray-Longeras P; Frenel JS; Bachelot T; Mailliez A; Brain E; Desmoulins I; Massard V; Patsouris A; Goncalves A; Grinda T; Delaloge S; Bellera C
    Eur J Cancer; 2024 Jan; 196():113422. PubMed ID: 37977105
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systematic literature review of real-world evidence for treatments in HR+/HER2- second-line LABC/mBC after first-line treatment with CDK4/6i.
    Lambert V; Kane S; Howidi B; Nguyen BN; Chandiwana D; Wu Y; Edwards M; Samjoo IA
    BMC Cancer; 2024 May; 24(1):631. PubMed ID: 38783218
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-World Patient Characteristics, Utilization Patterns, and Outcomes of US Patients with HR+, HER2- Metastatic Breast Cancer Treated with Abemaciclib.
    Smyth EN; Beyrer J; Saverno KR; Hadden E; Abedtash H; DeLuca A; Lawrence GW; Rybowski S
    Drugs Real World Outcomes; 2022 Dec; 9(4):681-693. PubMed ID: 36097254
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective Cohort Study of Combination Therapy With Abemaciclib and Hormonal Therapy for Chemotherapy-Treated Patients With Hormone Receptor-Positive Metastatic Breast Cancer.
    Miyahara K; Narui K; Uemura Y; Yamada A; Araki K; Fujisawa F; Nakayama T; Ishikawa T; Taira N; Kikawa Y; Aihara T; Mukai H
    World J Oncol; 2022 Aug; 13(4):216-221. PubMed ID: 36128594
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systemic Therapies Following Progression on First-line CDK4/6-inhibitor Treatment: Analysis of Real-world Data.
    Martin JM; Handorf EA; Montero AJ; Goldstein LJ
    Oncologist; 2022 Jun; 27(6):441-446. PubMed ID: 35552450
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative effectiveness of first-line palbociclib plus letrozole versus letrozole alone for HR+/HER2- metastatic breast cancer in US real-world clinical practice.
    DeMichele A; Cristofanilli M; Brufsky A; Liu X; Mardekian J; McRoy L; Layman RM; Emir B; Torres MA; Rugo HS; Finn RS
    Breast Cancer Res; 2021 Mar; 23(1):37. PubMed ID: 33761995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-World Outcomes of Trastuzumab Deruxtecan in Patients With HER2+ Metastatic Breast Cancer: The DE-REAL Study.
    Botticelli A; Caputo R; Scagnoli S; Pisegna S; De Laurentiis M; Curigliano G; Lambertini M; Pantano F; Palazzo A; Paris I; Vernieri C; Tedesco B; Giampaglia M; Palleschi M; Ballatore Z; Alesini D; D'Auria G; Fabbri A; Rossi L; Verrazzo A; Scafetta R; Marinelli D; Sposetti C; Barberi V; Strigari L; Marchetti P; Santini D; Fabi A
    Oncologist; 2024 Apr; 29(4):303-310. PubMed ID: 37995313
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between progression-free survival and overall survival in women receiving first-line treatment for metastatic breast cancer: evidence from the ESME real-world database.
    Courtinard C; Gourgou S; Jacot W; Carton M; Guérin O; Vacher L; Bertaut A; Le Deley MC; Pérol D; Marino P; Levy C; Uwer L; Perrocheau G; Schiappa R; Bachelot F; Parent D; Breton M; Petit T; Filleron T; Loeb A; Mathoulin-Pélissier S; Robain M; Delaloge S; Bellera C
    BMC Med; 2023 Mar; 21(1):87. PubMed ID: 36882736
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-World Treatment Patterns and Outcomes of Palbociclib Plus an Aromatase Inhibitor for Metastatic Breast Cancer: Flatiron Database Analysis.
    Patt D; Liu X; Li B; McRoy L; Layman RM; Brufsky A
    Clin Breast Cancer; 2022 Aug; 22(6):601-610. PubMed ID: 35643624
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: safety and patient-reported outcomes from the monarchE study.
    Rugo HS; O'Shaughnessy J; Boyle F; Toi M; Broom R; Blancas I; Gumus M; Yamashita T; Im YH; Rastogi P; Zagouri F; Song C; Campone M; San Antonio B; Shahir A; Hulstijn M; Brown J; Zimmermann A; Wei R; Johnston SRD; Reinisch M; Tolaney SM;
    Ann Oncol; 2022 Jun; 33(6):616-627. PubMed ID: 35337972
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Observational study of HR+/HER2- metastatic breast cancer patients treated with abemaciclib in Spain in the Named Patient Use Program (AbemusS).
    Blanch S; Gil-Gil JM; Arumí M; Aguirre E; Seguí MÁ; Atienza M; Díaz-Cerezo S; Molero A; Cervera JM; Gavilá J
    Clin Transl Oncol; 2023 Oct; 25(10):2950-2959. PubMed ID: 37029241
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Abemaciclib plus fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in premenopausal women: subgroup analysis from the MONARCH 2 trial.
    Neven P; Rugo HS; Tolaney SM; Iwata H; Toi M; Goetz MP; Kaufman PA; Lu Y; Haddad N; Hurt KC; Sledge GW
    Breast Cancer Res; 2021 Aug; 23(1):87. PubMed ID: 34425869
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.